rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    EDIT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study
      Nov 10Yahoo FinanceEDIT
      Editas at guggenheim healthcare innovation conference: focused on in vivo CRISPR
      Nov 10Investing.comEDIT
      Editas Medicine earnings beat by $0.04, revenue topped estimates
      Nov 9Investing.comEDIT
      Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
      Nov 9Yahoo FinanceEDIT
      Editas: Q3 Earnings Snapshot
      Nov 9Yahoo FinanceEDIT
      Editas Medicine Announces Third Quarter 2026 Results and Business Updates
      Nov 9Yahoo FinanceEDIT
      Jones Trading initiates Editas Medicine stock coverage with buy rating
      Nov 5Investing.comEDIT
      Editas Medicine to present gene editing research at ESGCT congress
      Oct 14Investing.comEDIT
      Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift
      Oct 12Seeking AlphaEDIT
      EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
      Oct 9Yahoo FinanceEDIT
      Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401
      Oct 8Yahoo FinanceEDIT
      Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
      Oct 8Yahoo FinanceEDIT
      Editas wins Australia nod for gene editing trial (EDIT:NASDAQ)

      Editas Medicine (EDIT) stock gains as Wells Fargo upgrades after Australia clears the first-in-human trial for the firm's gene editing drug, EDIT-401. Read more here.

      Oct 8Seeking AlphaEDIT
      Wells Fargo Upgrades Editas Medicine to Overweight From Equal Weight, $6 Price Target
      Oct 8Yahoo FinanceEDIT
      Editas Medicine Receives Approval in Australia for Phase 3 Trial of EDIT-401 to Treat Hyperlipidemia
      Oct 8Yahoo FinanceEDIT
      Editas Medicine receives approval to start EDIT-401 trial in Australia
      Oct 8Investing.comEDIT
      Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
      Oct 8Yahoo FinanceEDIT
      Editas stock raised to Buy at Guggenheim (EDIT:NASDAQ)
      Sep 23Seeking AlphaEDIT
      TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On

      U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.

      Sep 23BenzingaEDITTLSI
      This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Microsoft (NASDAQ:MSF

      Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.

      Sep 23BenzingaEDIT
      Why is Editas Medicine stock rallying today?
      Sep 23Investing.comEDIT
      Guggenheim upgrades Editas Medicine stock rating on gene editing therapy
      Sep 23Investing.comEDIT
      Guggenheim Upgrades Editas Medicine to Buy From Neutral, Price Target is $5

      Editas Medicine (EDIT) has an average rating of overweight and mean price target of $4.88, according

      Sep 23Yahoo FinanceEDIT
      Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

      Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol. Speaking at the Cantor Healthcare Conference, President and Chief Executive

      Sep 12Yahoo FinanceEDIT
      Editas Medicine at Cantor conference: in vivo CRISPR push advances
      Sep 10Investing.comEDIT
      Editas Medicine grants stock options to new chief medical officer
      Sep 9Investing.comEDIT
      Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

      Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O’Neill said during a Wells Fargo discussion. O’Ne

      Sep 9Yahoo FinanceEDIT
      Editas Medicine Reports Inducement Grants to New Chief Medical Officer

      CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Daniel Ory, M.D. In connection with Dr. Ory’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Ory as an inducement material to Dr. Ory entering into employment with Editas

      Sep 9Yahoo FinanceEDIT
      Editas Medicine at Wells Fargo conference: a focused bet on CRISPR
      Sep 8Investing.comEDITWFC
      Editas Medicine names Dan Ory as chief medical officer
      Sep 8Investing.comEDIT
      Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
      Sep 8Yahoo FinanceEDIT
      Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
      Sep 4Yahoo FinanceEDIT
      Editas - Slow Progress Doesn't Mean No Progress For In-Vivo Gene Editor (NASDAQ:EDIT)
      Sep 2Seeking AlphaEDIT
      Editas Medicine to Participate in Upcoming Investor Conferences

      CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, September 8Time: 4:30 p.m. ET Location: Boston, MA 2026 Cantor Global Healthcare ConferenceFormat: Fireside Chat Date: Thursday

      Sep 1Yahoo FinanceEDIT
      Editas Medicine Files $400 Million Mixed Shelf

      Editas Medicine (EDIT) filed a registration statement Monday with the US Securities and Exchange Com

      Aug 31Yahoo FinanceEDIT

      This is the newest page. Registered accounts read further back.